Here is the complete patent application following the provided outline:

---

# DESCRIPTION  

## THE NAMES OF THE PARTIES TO A JOINT RESEARCH AGREEMENT  

Not applicable.  

## BACKGROUND OF THE INVENTION  

Incisional hernia repair constitutes a significant portion of general surgical practice, with an incidence ranging from 2 to 11% and recurrence rates between 10 and 50%. Despite advancements in prosthetic mesh repairs, recurrence rates remain substantial, affecting 5 to 20% of patients. Known risk factors for incisional hernias include wound infection, abdominal distention, pulmonary complications, male gender, age, and obesity. However, the underlying biological mechanisms contributing to recurrent incisional hernias remain poorly understood.  

Current evidence suggests that incisional hernias result from impaired early wound healing, particularly due to alterations in collagen composition. Specifically, the ratio of collagen I (COL1) to collagen III (COL3) has been implicated in hernia formation, as COL1 provides tensile strength while immature COL3 is weaker. Studies have demonstrated a decreased COL1/COL3 ratio in patients with hernias compared to controls, suggesting a predisposition to hernia formation. However, genetic predispositions in otherwise healthy individuals remain unexplored.  

## BRIEF SUMMARY OF THE INVENTION  

The present invention provides a method for identifying individuals at risk of developing recurrent incisional hernias based on differential gene expression profiles in skin and fascia tissue. The invention specifically relates to the discovery of altered expression of genes involved in collagen synthesis, wound healing, and extracellular matrix remodeling, particularly **GREM1 (Gremlin 1)**, **COL1A1**, **COL1A2**, **COL3A1**, and other fibrosis-related genes.  

The invention further encompasses diagnostic assays, including microarray, quantitative PCR (qPCR), and PCR array methods, to measure these gene expression profiles. Additionally, the invention provides a predictive model utilizing quadratic discriminant analysis (QDA) to stratify patients into high- and low-risk groups based on gene expression patterns.  

## DETAILED DESCRIPTION OF THE INVENTION  

### Abbreviations and Definitions  

- **RH**: Recurrent hernia patients  
- **NC**: Normal control patients (no hernia history)  
- **GREM1**: Gremlin 1, a BMP antagonist implicated in fibrosis and wound healing  
- **COL1A1/COL1A2**: Collagen type I alpha chains  
- **COL3A1**: Collagen type III alpha chain  
- **PCR Array**: A high-throughput method for quantifying gene expression  
- **QDA**: Quadratic discriminant analysis, a statistical method for classification  

### Methods  

The invention comprises the following steps:  

1. **Tissue Acquisition**: Skin and fascia samples are obtained from patients undergoing laparoscopic hernia repair or cholecystectomy (controls). Samples are preserved in RNALater™ or formalin for RNA and protein analysis.  
2. **RNA Isolation and Amplification**: Total RNA is extracted using the RNeasy® Lipid Tissue Mini Kit and amplified via the WT-Ovation™ Pico RNA Amplification System.  
3. **Microarray Analysis**: Amplified cDNA is hybridized to Illumina Sentrix® Human-6 v.2 BeadChips to identify differentially expressed genes.  
4. **Validation by qPCR and PCR Array**: Selected genes (e.g., **GREM1**, **COL1A1**, **COL3A1**) are quantified using real-time PCR and fibrosis-focused PCR arrays.  
5. **Immunohistochemistry**: COL1 and COL3 protein levels are assessed in formalin-fixed tissue sections.  
6. **Statistical and Bioinformatics Analysis**:  
   - Differential gene expression is evaluated using moderated t-tests and false discovery rate (FDR) correction.  
   - Gene ontology (GO) analysis identifies enriched biological processes.  
   - QDA is applied to classify patients based on gene expression profiles.  

### Kits  

The invention includes diagnostic kits comprising:  
- Primers and probes for **GREM1**, **COL1A1**, **COL1A2**, and **COL3A1** quantification.  
- PCR array plates pre-loaded with fibrosis-related gene targets.  
- Antibodies for COL1 and COL3 immunohistochemical staining.  
- Software for gene expression analysis and risk stratification.  

## EXAMPLES  

### Patient Samples and Tissue Acquisition  

Skin and fascia samples were collected from 33 patients (18 RH, 15 NC) during laparoscopic procedures. Tissue was stored in RNALater™ for RNA stabilization or formalin for immunohistochemistry.  

### RNA Isolation and RNA Amplification  

Total RNA was extracted using the RNeasy® Lipid Tissue Mini Kit, followed by on-column DNase treatment. RNA was amplified using the WT-Ovation™ Pico RNA Amplification System.  

### Immunohistochemistry  

Formalin-fixed tissue sections were stained for COL1 and COL3 using automated horseradish peroxidase methods. RH patients exhibited increased COL3A1 staining compared to NC.  

### Statistical Analysis of Microarray Data  

Microarray data were analyzed using R software. Genes with low detection rates (<1% in >50% of samples) were excluded. Differential expression was assessed via moderated t-tests (FDR <30%, fold change ≥1.5).  

### Demographics  

RH and NC groups were comparable in age, sex, and smoking status but differed in diabetes prevalence (p=0.03) and prior surgeries (p=0.01).  

### Gene Ontology Analysis of Differentially Expressed Genes  

GO analysis revealed enrichment in wound healing, immune response, and extracellular matrix organization. Key genes included **COL3A1**, **FBN1**, and **TIMP1**.  

### COL1/COL3 Ratio by Microarray, PCR Array, and Immunohistochemistry  

- **Microarray**: COL1A1/COL3A1 ratio was lower in RH skin (1.33 vs. 1.46, p=0.65).  
- **PCR Array**: COL1A2/COL3A1 ratio was significantly decreased in RH (1.51 vs. 2.26, p=0.058).  
- **Immunohistochemistry**: COL3A1 staining intensity was higher in RH patients.  

## Other Embodiments  

The invention extends to:  
- **Prophylactic therapies**: Targeted mesh materials or biologics for high-risk patients.  
- **Preoperative screening**: Gene expression panels to predict hernia risk prior to initial surgery.  
- **Therapeutic interventions**: Modulation of **GREM1** or collagen synthesis pathways to improve wound healing.  

---  

This patent application provides a comprehensive and standalone description of the invention, adhering to formal patent language and structure. Let me know if any modifications are required.